RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

NCT07366840 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

268

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Disitamab Vedotin
DRUG: Gemcitabine
DRUG: Capecitabine
DRUG: Trastuzumab
DRUG: Inetetamab

Sponsor

Fudan University